spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  excipient 

 HSMN NewsFeed - 10 Nov 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables
Biopharmaceuticals Generics Mergers & Acquisitions
 HSMN NewsFeed - 17 Mar 2025
Surf Bio Appoints Industry Veteran Doug Hecker as Head of Technical Operations
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 7 Feb 2025
Most Patients on Lilly's Omvoh(R) (mirikizumab-mrkz) for Crohn's Disease Achieved Sustained Clinical Remission and Endoscopic Response at Two Years
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 29 Oct 2024
Protega Pharmaceuticals Receives FDA Approval for ROXYBOND(TM) (oxycodone hydrochloride) Immediate-Release 10 mg Tablet with Abuse-Deterrent Technology for Management of Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Aug 2024
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Jun 2024
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R)) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Nov 2023
Vaccine Partner Valneva receives FDA approval for the World's first chikungunya vaccine using Albumedix' Recombumin(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Aug 2023
AbbVie Announces European Commission Approval of AQUIPTA(R) (atogepant) for the Preventive Treatment of Migraine in Adults
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 2 Feb 2023
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 21 Oct 2022
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 19 Sep 2022
AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI(R)) for the Treatment of Adults with Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 4 Aug 2022
Amgen to Acquire Chemocentryx for $4 Billion in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 30 Mar 2022
Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jan 2022
PANTHERx Rare(R) Selected by Xeris Pharmaceuticals to Distribute Recorlev(R) (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients with Cushing's Syndrome
Biopharmaceuticals Distribution
 HSMN NewsFeed - 24 Aug 2021
European Commission Approves RINVOQ(R) (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 11 Dec 2020
CHMP Recommends the Approvals of RINVOQ(TM) (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Nov 2020
TheraCell Announces First Surgical Use Of TheraFuze DBF(R) Fiber Anchor(TM) For Pedicle Screw Augmentation
Devices Orthopaedic Neurosurgery
 HSMN NewsFeed - 31 Aug 2020
Mylan and Biocon Biologics Announce Launch of Semglee(TM) (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 1 Jun 2020
Lilly's Taltz(R) (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 May 2020
Emgality(R) Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Mar 2020
Lilly's Taltz(R) (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 12 Mar 2020
AbbVie Receives European Commission Approval of VENCLYXTO(R) Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Feb 2020
Crescita Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Studies for its Lead Pipeline Product in Patients with Plaque Psoriasis
Biopharmaceuticals Drug Delivery Dermatology
 HSMN NewsFeed - 31 Jan 2020
AbbVie Receives Positive CHMP Opinion for VENCLYXTO(R) as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Jan 2020
Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities
Biopharmaceuticals Drug Delivery Endocrinology
 HSMN NewsFeed - 18 Dec 2019
Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality(R) (galcanezumab-gnlm)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz(R) (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
Biopharmaceuticals
 HSMN NewsFeed - 3 Oct 2019
New Head-to-Head Data Show Taltz(R) (ixekizumab) Superiority versus TREMFYA(R) (guselkumab) in People with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 26 Aug 2019
Lilly Receives U.S. FDA Approval for Taltz(R) (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Aug 2019
Amgen To Acquire Otezla(R) For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 13 Aug 2019
FDA Approves EYLEA(R) (aflibercept) Injection Prefilled Syringe
Biopharmaceuticals Drug Delivery Ophthalmology FDA
 HSMN NewsFeed - 5 Aug 2019
Lilly Announces Positive Results for Emgality(R) (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
Biopharmaceuticals Neurology
 HSMN NewsFeed - 12 Jul 2019
AHS 2019: Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality(R) (galcanezumab-gnlm) Show Improvements in Daily Functioning and Reductions in Disability in Patients with Chronic and Episodic Migraine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Jul 2019
New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality(R) (galcanezumab-gnlm) in Episodic Cluster Headache
Biopharmaceuticals Neurology
 HSMN NewsFeed - 14 Jun 2019
Lilly Presents Positive Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology
Biopharmaceuticals
 HSMN NewsFeed - 11 Jun 2019
Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz(R) (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 30 May 2019
U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA(R) (gilteritinib)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Apr 2019
Neurelis Announces Completion of Senior Management Team Buildout to Support the Anticipated Commercial Launch of VALTOCO(TM)
Biopharmaceuticals Drug Delivery Neurology Personnel
 HSMN NewsFeed - 17 Dec 2018
Lilly Announces Positive Top-Line Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 3 Dec 2018
Neurelis Announces Acquisition Of Aegis Therapeutics, A Leading Drug Delivery Technology Company
Biopharmaceuticals Drug Delivery Mergers & Acquisitions
 HSMN NewsFeed - 14 Nov 2018
Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality(TM) (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 1 Nov 2018
AbbVie Receives European Commission Approval of VENCLYXTO(R) (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Oct 2018
EYLEA(R) (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 13 Sep 2018
FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 13 Sep 2018
AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 10 Sep 2018
Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz(R) and Tremfya(R) in Patients with Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals
 HSMN NewsFeed - 17 Aug 2018
FDA Approves EYLEA(R) (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 28 Jun 2018
Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
Biopharmaceuticals
 HSMN NewsFeed - 15 Jun 2018
Medtronic Receives FDA Approval for 200mm & 250mm IN.PACT(TM) Admiral(TM) Drug Coated Balloons
Devices Interventional FDA
 HSMN NewsFeed - 15 Jun 2018
AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 May 2018
UCB Announces the Approval of CIMZIA(R) (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 27 Apr 2018
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia(R) (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Apr 2018
Biopharm Startup TFF Pharmaceuticals Raises $14M for Breakthrough Dry Powder Inhalation Platform
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 23 Mar 2018
Amgen Receives Positive CHMP Opinion Recognizing That Repatha(R) (evolocumab) Prevents Heart Attacks And Strokes
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 27 Feb 2018
Abbott and Surmodics Announce Agreement for Next-Generation Drug-Coated Balloon
Devices Interventional Licensing
 HSMN NewsFeed - 23 Feb 2018
Amgen Receives Positive Opinion Expanding Use Of XGEVA(R) (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Feb 2018
AAD 2018: Treatment with Lilly's Taltz(R) (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 13 Feb 2018
Lilly Announces Positive Top-Line Phase 3 Results for Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2017
EMD Serono Receives FDA Approval for New GONAL-f(R) RFF Redi-ject(R) Pen
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 8 Nov 2017
Long-Term Use of Lilly's Taltz(R) (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors
Biopharmaceuticals
 HSMN NewsFeed - 20 Oct 2017
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 25 Jul 2017
HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 21 Jul 2017
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human])
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jun 2017
EULAR 2017: Lilly's Taltz(R) (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks
Biopharmaceuticals
 HSMN NewsFeed - 16 Jun 2017
New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017
Biopharmaceuticals
 HSMN NewsFeed - 26 Apr 2017
Inspirion Delivery Sciences Receives FDA Approval for RoxyBond(TM) (oxycodone hydrochloride) tablets CII, the First and Only Immediate Release Opioid Analgesic with Abuse-Deterrent Label Claims
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 16 Mar 2017
Shire Receives European Approval for Label Extension of CINRYZE(R) (C1 inhibitor ) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Feb 2017
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 8 Feb 2017
FDA Approves Amgen's Parsabiv(TM) (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 11 Jan 2017
Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv(TM) (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis
Biopharmaceuticals
 HSMN NewsFeed - 27 Dec 2016
Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Dec 2016
Sobi and Horizon Pharma Enter Five-Year Distribution Agreement for Ravicti(R) and Ammonaps(R) Outside the United States
Biopharmaceuticals Distribution
 HSMN NewsFeed - 14 Nov 2016
AbbVie's HUMIRA(R) (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 31 Aug 2016
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 29 Aug 2016
New Repatha(R) (evolocumab) Analyses Show Efficacy and Safety Across Risk Groups in Results Presented at ESC Congress 2016
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 1 Aug 2016
Shire Announces FDA Approval of adynovate with BAXJECT III Reconstitution System
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Jul 2016
Shire Receives Extension of Market Authorization in Europe for Revestive(R) (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 May 2016
AbbVie's HUMIRA(R) (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 4 Apr 2016
AbbVie Receives CHMP Positive Opinion for HUMIRA(R) (adalimumab) for the Treatment of Pediatric Patients, from Six Years of Age, with Moderately to Severely Active Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 4 Feb 2016
Sigmoid Pharma Announces Acquisition of Freund Pharmatec Ltd.
Biopharmaceuticals Drug Delivery Mergers & Acquisitions
 HSMN NewsFeed - 1 Feb 2016
Mallinckrodt Completes Acquisition Of Three Commercial-Stage, Global Specialty Hemostasis Brands From The Medicines Company
Devices Surgery Acquisitions
 HSMN NewsFeed - 16 Jan 2016
Novartis receives two new FDA approvals for Cosentyx(R) (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Oct 2015
Celgene’s VIDAZA(R) (Azacitidine for Injection) Approved by the European Commission as New Treatment for Elderly Patients with Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Aug 2015
European Commission Grants Marketing Authorisation for Unituxin(TM) (dinutuximab) for the Treatment of Paediatric High-Risk Neuroblastoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Jul 2015
Dauntless Pharmaceuticals and Aegis Therapeutics Announce Licensing Agreement
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 18 May 2015
Actavis Launches NAMZARIC(TM) (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer's Disease
Biopharmaceuticals Neurology Product Launch
 HSMN NewsFeed - 20 Apr 2015
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 Mar 2015
The Medicines Company Receives European Commission Approval for Three Hospital Acute Care Products: KENGREXAL(TM) (cangrelor), ORBACTIV(R) (oritavancin) and RAPLIXA(TM) (sealant powder)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Mar 2015
Daiichi Sankyo Signs Agreement With AstraZeneca To Co-Commercialize MOVANTIK In The US
Biopharmaceuticals
 HSMN NewsFeed - 20 Feb 2015
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Nov 2014
Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 19 Sep 2014
European Commission Grants Marketing Authorization for Gilead’s Zydelig(R) (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Aug 2014
Sanofi and MannKind Announce Global Licensing Agreement for Afrezza(R) (insulin human) Rapid-Acting Inhaled Insulin
Biopharmaceuticals Endocrinology Drug Delivery Licensing
 HSMN NewsFeed - 24 Jul 2014
Boston Scientific Receives CE Mark For Agent(TM) Drug-Coated Balloon
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 27 Jun 2014
EYLEA(R) (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 11 Jun 2014
GSK and Theravance Announce Positive Data From Two Studies Evaluating the Efficacy and Safety of Incruse(TM) Ellipta(R) When Added to Relvar(R)/Breo(R) Ellipta(R) in Patients With COPD
Biopharmaceuticals
 HSMN NewsFeed - 21 May 2014
Baxter Provides U.S. Regulatory Update on HyQvia, Its Investigational Subcutaneous Treatment for Primary Immunodeficiency
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Mar 2014
Mallinckrodt plc Completes $1.4 Billion Acquisition of Cadence Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Feb 2014
Mallinckrodt plc to Acquire Cadence Pharmaceuticals, Inc. for $14.00 Per Share, in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Feb 2014
Two-Year Results From Phase 3 VISTA Trial of EYLEA(R) (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 17 Jan 2014
European Commission Grants Marketing Authorization for Gilead’s Sovaldi(R) (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Dec 2013
Regeneron Announces FDA Acceptance of EYLEA(R) (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 16 Dec 2013
EMD Serono's Redesigned Fertility Pen Available for Distribution in US
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 22 Nov 2013
EYLEA(R) (aflibercept) Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 22 Oct 2013
Pfizer Proceeding with REMOXY(R) Development
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Sep 2013
Cimzia(R) (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Sep 2013
Par Pharmaceutical Begins Shipment of Generic Glucotrol XL(R)
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 20 Sep 2013
RELVAR(TM) ELLIPTA(TM) Gains Approval in Japan for the Treatment of Asthma
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Jul 2013
EYLEA(R) (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 17 May 2013
New Study Shows Effect of Neupro(R) (Rotigotine Transdermal System) on Cardiovascular Measures in Patients with Restless Legs Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 1 Apr 2013
Ferro Announces Sale of Its Pharmaceuticals Business
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 19 Feb 2013
Regeneron and Bayer Initiate Phase 3 Trial of EYLEA(R) (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 6 Dec 2012
EYLEA(R) (aflibercept) Submitted for EU Marketing Authorization for the Treatment of Macular Edema Following Central Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 27 Nov 2012
EYLEA(R) (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 19 Nov 2012
ZYTIGA(R) Receives Positive Regulatory Recommendation in the European Union for Treatment of Metastatic Castration-Resistant Prostate Cancer before Chemotherapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Sep 2012
Apricus Biosciences' Wholly-Owned Subsidiary NexMed (U.S.A.) and Takeda Pharmaceuticals International GmbH Sign Exclusive License Agreement to Market Vitaros(R) in the United Kingdom
Biopharmaceuticals Licensing
 HSMN NewsFeed - 16 Jul 2012
UCB Launches Neupro(R) in the U.S. to Treat Parkinson’s Disease and Restless Legs Syndrome
Biopharmaceuticals Neurology Drug Delivery
 HSMN NewsFeed - 16 May 2012
Armando Anido Joins Respira Therapeutics, Inc. Board of Directors
Devices Drug Delivery Personnel
 HSMN NewsFeed - 13 Apr 2012
Medtronic Initiates Landmark U.S. Drug-Eluting Balloon Study
Devices Interventional
 HSMN NewsFeed - 3 Apr 2012
Neupro(R) Approved by U.S. FDA for Parkinson’s Disease and Restless Legs Syndrome
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 8 Mar 2012
Regeneron and Bayer Announce Approval of EYLEA(R) (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration in Australia
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 6 Dec 2011
Amneal Announces Corporate Business Development Team
Biopharmaceuticals Generics Personnel
 HSMN NewsFeed - 6 Sep 2011
ViroPharma's Buccolam(R) (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 31 Aug 2011
Baxter Announces FDA Approval of ARTISS Fibrin Sealant for Use in Face-Lift (Facial Rhytidectomy) Procedures
Devices FDA
 HSMN NewsFeed - 20 Jun 2011
Pulmatrix Launches iSPERSE(TM), A Novel Inhaled Dry Powder Drug Delivery Platform
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 4 Apr 2011
BIOTRONIK Announces Positive 6-month Results for Pantera(R) Lux Paclitaxel Releasing Balloon
Devices Interventional Cardiology
 HSMN NewsFeed - 18 Jan 2011
Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV (acetaminophen) Injection
Biopharmaceuticals
 HSMN NewsFeed - 15 Nov 2010
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 11 Nov 2010
FDA Approves EGRIFTA(TM) (Tesamorelin for Injection): The First and Only Treatment for the Reduction of Excess Abdominal Fat in HIV-Infected Patients With Lipodystrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Nov 2010
Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV (acetaminophen) injection for the Management of Pain and Fever
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jul 2010
Study Showed the Clinically Significant Therapeutic Benefit of Neupro(R) (rotigotine transdermal system) in the Treatment of Restless Legs Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 7 Jul 2010
European Commission Approves ORENCIA in Combination with Methotrexate for Earlier Use as First-Line Biologic after DMARD Inadequate Response for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Jul 2010
Phase III Study Shows Novartis Drug Afinitor(R) More Than Doubles Time Without Tumor Growth in Advanced Pancreatic NET Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jun 2010
Investigational BRINAVESS (vernakalant) for Infusion Recommended for Approval by the CHMP in the European Union (EU) for the Rapid Conversion of Recent Onset Atrial Fibrillation
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 18 Jun 2010
Neupro(R) (rotigotine) significantly improved wellbeing and daily activities impaired due to limb pain associated with Restless Legs Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 17 Jun 2010
Neupro(R) (rotigotine transdermal system) Showed Significant Benefit on Early Morning Motor Control, Sleep and Nocturnal Symptoms in Patients With Parkinson's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Jun 2010
Pivotal Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Apr 2010
UCB Receives Complete Response Letter from U.S. FDA Regarding Neupro(R) (Rotigotine)
Biopharmaceuticals Drug Delivery Neurology FDA
 HSMN NewsFeed - 13 Apr 2010
New Data Show Sustained 5-Year Benefit of Neupro(R) (Rotigotine Transdermal System) for Symptoms of Restless Legs Syndrome
Biopharmaceuticals Neurology Drug Delivery
 HSMN NewsFeed - 29 Jan 2010
Study Published in the American Journal of Ophthalmology Examines Investigational Use of Macugen in Patients With Branch Retinal Vein Occlusion (BRVO)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 29 Jan 2010
Teva UK Limited Launches Lercanidipine Hydrochloride Film-Coated Tablets
Biopharmaceuticals Generics
 HSMN NewsFeed - 28 Jan 2010
Teva UK Limited Launches Dorzolamide 2% Eye Drops Solution
Biopharmaceuticals Generics Ophthalmology
 HSMN NewsFeed - 16 Dec 2009
Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent
Biopharmaceuticals Drug Delivery Venture Capital
 HSMN NewsFeed - 29 Oct 2009
Ipsen Announces the Launch of Dysport(R) (abobotulinumtoxinA) in the United States for the Treatment of Cervical Dystonia
Biopharmaceuticals
 HSMN NewsFeed - 6 Oct 2009
SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Jun 2009
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Jun 2009
Clinical Data Presented at International Congress Showed Treatment With Neupro(R) (rotigotine) Significantly Improved Early Morning akinesia and was Generally Well Tolerated Over Four Years
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 May 2009
UCB receives CHMP positive opinion on bringing Neupro(R) back to all patients in Europe
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 20 Feb 2009
UCB to divest Equasym(R)
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 11 Dec 2008
New Data Shows Zometa(R) Enhances Impact of Chemotherapy on Reducing Breast Tumour Size
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jul 2008
New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Jun 2008
Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Jun 2008
Merck & Co., Inc Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL(R) in Women Ages 27 through 45
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jun 2008
Tercica Announces Results from Increlex(R) IGFD Patient Registry and Other Increlex(R) Studies at the 90th Meeting of the Endocrine Society
Biopharmaceuticals
 HSMN NewsFeed - 10 Jun 2008
Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 3 Jun 2008
New Abbott Aluvia(R) Tablet for Treatment of HIV Available in South Africa
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 31 May 2008
Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Premenopausal Women With Early-Stage Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Apr 2008
Jazz Pharmaceuticals' LUVOX CR Is Now Available for Patients With Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
Biopharmaceuticals
 HSMN NewsFeed - 7 Apr 2008
New Abbott Kaletra(R) (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 3 Apr 2008
Excipients Help Pharma Extend Product Life, Profits
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 19 Mar 2008
Supplemental Application for GARDASIL(R), Merck's Cervical Cancer Vaccine, Designated Priority Review by the U.S. FDA for Use in Women 27 through 45
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2008
FDA Approves LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Feb 2008
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Biopharmaceuticals
 HSMN NewsFeed - 21 Feb 2008
Lilly Launches KwikPen(TM) for Humalog(R) and Humalog Mixtures
Biopharmaceuticals Drug Delivery Endocrinology
 HSMN NewsFeed - 31 Jan 2008
Encysive Pharmaceuticals Launches THELIN (Sitaxentan Sodium) in Sweden
Biopharmaceuticals
 HSMN NewsFeed - 28 Jan 2008
Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 14 Jan 2008
Encysive Pharmaceuticals Launches THELIN (sitaxentan sodium) in Belgium and Luxembourg
Biopharmaceuticals
 HSMN NewsFeed - 27 Dec 2007
Endo Pharmaceuticals to Develop and Commercialize Alexza's AZ-003 Staccato(R) Inhaled Fentanyl Product
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 28 Nov 2007
Tasigna(R) gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Nov 2007
Encysive Pharmaceuticals Launches Thelin (sitaxentan sodium) in Italy
Biopharmaceuticals
 HSMN NewsFeed - 4 Nov 2007
New Data Presented on GARDASIL(R), Merck's Cervical Cancer Vaccine, in Women Through Age 45
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Oct 2007
Tasigna(R) receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Oct 2007
FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Sep 2007
Merck to Donate Three Million Doses of Gardasil(R), its Cervical Cancer Vaccine, to Support Vaccination Programs in Lowest Income Nations
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Sep 2007
Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Sep 2007
Encysive Pharmaceuticals Announces Launch of THELIN (sitaxentan sodium) in Spain
Biopharmaceuticals
 HSMN NewsFeed - 31 Aug 2007
Ipsen: Somatuline(R) Depot Receives Marketing Approval in the United States for the Treatment of Acromegaly
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 30 Aug 2007
Somatuline(R) Depot Receives FDA Marketing Approval for the Treatment of Acromegaly
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Jul 2007
Abbott Submits E.U. and U.S. Regulatory Filings for New Lower-Strength Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) Tablet Suitable for Pediatric Use in HIV/AIDS
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 9 Jul 2007
Pro-Pharmaceuticals Updates Progress of Clinical Trials & DAVANAT(R) 505 (b)(2) Filings
Biopharmaceuticals Oncology Drug Delivery
 HSMN NewsFeed - 25 Jun 2007
New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir(R)
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 20 Jun 2007
Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Jun 2007
FDA Approves Norditropin(R)for Treatment of Short Stature Associated with a Rare Genetic Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 May 2007
Canadian Health Authority Approves THELIN (Sitaxsentan Sodium) for Pulmonary Arterial Hypertension
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 May 2007
Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of LIALDA(TM) (mesalamine) Presented at DDW
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 17 May 2007
Data Published in The Lancet Show GARDASIL(R) was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
Biopharmaceuticals
 HSMN NewsFeed - 17 May 2007
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 9 May 2007
New England Journal of Medicine Publishes New Data on GARDASIL(R), Merck's Cervical Cancer Vaccine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Apr 2007
Indevus Announces Submission of Supplemental NDA to Reintroduce VALSTAR(R) to Treat Bladder Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2007
Merck Submits New Cross-Protection Data for GARDASIL(R) to the FDA and Seeks New Indications for Vaginal and Vulvar Cancers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Apr 2007
Encysive Pharmaceuticals Announces Launch of THELIN (Sitaxentan Sodium) in the Netherlands
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Apr 2007
Pro-Pharmaceuticals Plans to Submit a New Drug Application for DAVANAT(R), as a Functional Excipient, with 5-FU to Treat Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2007
Pro-Pharmaceuticals Receives Letter from the FDA for New Drug Application for DAVANAT(R)/ 5-FU
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Apr 2007
Abbott Agrees With World Health Organization (WHO) Director-General to Expand Access to Kaletra/Aluvia (lopinavir/ritonavir)
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 2 Apr 2007
Encysive Pharmaceuticals Announces Launch of Thelin (Sitaxentan Sodium) in Republic of Ireland
Biopharmaceuticals
 HSMN NewsFeed - 22 Mar 2007
CDC Finalizes Advisory Panel Recommendations for GARDASIL(R), Merck's Cervical Cancer Vaccine
Biopharmaceuticals
 HSMN NewsFeed - 19 Mar 2007
LIALDA(TM) (mesalamine) With MMX(TM) Technology - the First Oral Once-Daily Mesalamine for Active, Mild to Moderate Ulcerative Colitis - Now Available
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 12 Mar 2007
New European Approval for Xyrem(R) Provides Significant Advance in the Treatment of Narcolepsy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Feb 2007
Lilly Introduces World's First Digital Insulin Pen With Memory
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 16 Jan 2007
FDA Approves LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 16 Jan 2007
Tercica Reports Somatuline(R) Autogel(R) NDA for Acromegaly Accepted for Filing by FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Jan 2007
FDA Accepts for Filing a New Drug Application (NDA) for Somatuline(R) Autogel(R)
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
Merck Launches National Advertising Campaign for GARDASIL(R), Merck's New Cervical Cancer Vaccine
Biopharmaceuticals
 HSMN NewsFeed - 2 Nov 2006
Tercica Reports Somatuline(R) Autogel(R) NDA for Acromegaly Submitted to FDA
Biopharmaceuticals
 HSMN NewsFeed - 1 Nov 2006
Merck's Cervical Cancer Vaccine, GARDASIL(R), Added to the CDC Vaccines for Children Contract
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Sep 2006
European Commission Approves GARDASIL(R), Merck's Cervical Cancer Vaccine
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 Jun 2006
Merck's New Cervical Cancer Vaccine, GARDASIL(R), Unanimously Recommended by CDC Advisory Panel for Vaccination of Girls and Women 11 to 26 Years
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jun 2006
Novo Nordisk Prevails in sanofi-aventis Challenge to Levemir(R) - Up to 24 Hours Duration of Action and Other Claims Upheld
Biopharmaceuticals Litigation
 HSMN NewsFeed - 26 Jun 2006
OSI Pharmaceuticals and Pfizer Announce Phase IV Macugen(R)(pegaptanib sodium injection) Maintenance Trial in Neovascular Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 Jun 2006
Preliminary Topline Efficacy Results from Phase II Data Show Macugen(R) (pegaptanib sodium injection) Maintained or Improved Vision in over 90 Percent of Patients with Macular Edema Associated with Central Retinal Vein Occlusion (CRVO)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 24 May 2006
UCB Completes Mutual Recognition Procedure for Equasym(TM) XL
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 4 May 2006
OSI Pharmaceuticals Summarizes Macugen(R) (pegaptanib sodium injection) Data Presented at Association for Research in Vision and Ophthalmology (ARVO) Meeting
Biopharmaceuticals Ophthalmology
Return to NewsFeed  

 Additional items found! 62

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 62 additional stories matching:
excipient
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.